Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Diabetic Retinopathy | 30 | 2024 | 87 | 8.180 |
Why?
|
Macular Edema | 28 | 2023 | 50 | 7.810 |
Why?
|
Macular Degeneration | 24 | 2024 | 59 | 5.250 |
Why?
|
Retinal Diseases | 20 | 2022 | 90 | 4.880 |
Why?
|
Angiogenesis Inhibitors | 22 | 2024 | 311 | 4.480 |
Why?
|
Vitreous Body | 23 | 2019 | 54 | 3.750 |
Why?
|
Tomography, Optical Coherence | 28 | 2023 | 130 | 3.530 |
Why?
|
Vitrectomy | 21 | 2021 | 52 | 3.320 |
Why?
|
Visual Acuity | 30 | 2024 | 194 | 3.160 |
Why?
|
Retina | 18 | 2023 | 213 | 2.830 |
Why?
|
Wet Macular Degeneration | 8 | 2024 | 25 | 2.260 |
Why?
|
Fluorescein Angiography | 18 | 2023 | 96 | 2.200 |
Why?
|
Ophthalmology | 9 | 2023 | 39 | 2.200 |
Why?
|
Vascular Endothelial Growth Factor A | 13 | 2024 | 407 | 2.040 |
Why?
|
Laser Coagulation | 9 | 2021 | 54 | 1.890 |
Why?
|
Uveitis | 6 | 2023 | 29 | 1.820 |
Why?
|
Sclera | 5 | 2021 | 11 | 1.800 |
Why?
|
Recombinant Fusion Proteins | 9 | 2023 | 557 | 1.790 |
Why?
|
Vitreoretinal Surgery | 6 | 2022 | 8 | 1.710 |
Why?
|
Aqueous Humor | 9 | 2008 | 23 | 1.670 |
Why?
|
Macula Lutea | 4 | 2020 | 19 | 1.640 |
Why?
|
Retinal Detachment | 9 | 2021 | 66 | 1.600 |
Why?
|
Endophthalmitis | 8 | 2022 | 21 | 1.510 |
Why?
|
Retinal Perforations | 6 | 2020 | 19 | 1.490 |
Why?
|
Antifungal Agents | 8 | 2010 | 117 | 1.440 |
Why?
|
Intravitreal Injections | 18 | 2023 | 67 | 1.410 |
Why?
|
Eye Diseases | 4 | 2021 | 53 | 1.390 |
Why?
|
Central Serous Chorioretinopathy | 2 | 2022 | 2 | 1.370 |
Why?
|
Choroidal Neovascularization | 10 | 2018 | 31 | 1.360 |
Why?
|
Intraocular Pressure | 10 | 2020 | 54 | 1.350 |
Why?
|
Humans | 147 | 2024 | 86601 | 1.340 |
Why?
|
Geographic Atrophy | 6 | 2024 | 11 | 1.300 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 8 | 2023 | 70 | 1.290 |
Why?
|
Metformin | 6 | 2024 | 128 | 1.230 |
Why?
|
Cataract Extraction | 6 | 2021 | 31 | 1.230 |
Why?
|
Triazoles | 8 | 2010 | 96 | 1.190 |
Why?
|
Anti-Bacterial Agents | 7 | 2019 | 746 | 1.120 |
Why?
|
Choroid Diseases | 3 | 2022 | 5 | 1.090 |
Why?
|
Aza Compounds | 4 | 2006 | 8 | 1.060 |
Why?
|
Pyrimidines | 8 | 2010 | 370 | 1.010 |
Why?
|
Antibodies, Monoclonal, Humanized | 8 | 2018 | 930 | 0.990 |
Why?
|
Quinolines | 4 | 2006 | 95 | 0.990 |
Why?
|
Diabetes Mellitus | 9 | 2024 | 806 | 0.960 |
Why?
|
Ranibizumab | 9 | 2016 | 15 | 0.940 |
Why?
|
Eye Infections, Fungal | 6 | 2010 | 14 | 0.940 |
Why?
|
Disease Management | 5 | 2018 | 327 | 0.940 |
Why?
|
Photochemotherapy | 4 | 2015 | 97 | 0.940 |
Why?
|
Iatrogenic Disease | 1 | 2023 | 69 | 0.910 |
Why?
|
Fluocinolone Acetonide | 3 | 2023 | 8 | 0.910 |
Why?
|
Iris Diseases | 2 | 2015 | 6 | 0.900 |
Why?
|
Eye Infections, Bacterial | 3 | 2019 | 14 | 0.820 |
Why?
|
Choroid | 8 | 2022 | 33 | 0.790 |
Why?
|
Sclerostomy | 2 | 2011 | 2 | 0.780 |
Why?
|
Diagnostic Techniques, Ophthalmological | 4 | 2018 | 16 | 0.730 |
Why?
|
Glucocorticoids | 9 | 2023 | 352 | 0.730 |
Why?
|
Microsurgery | 3 | 2017 | 84 | 0.720 |
Why?
|
Retinal Vessels | 4 | 2022 | 58 | 0.710 |
Why?
|
Fluoroquinolones | 6 | 2006 | 22 | 0.700 |
Why?
|
Aged | 45 | 2024 | 18402 | 0.690 |
Why?
|
Polyps | 2 | 2018 | 28 | 0.690 |
Why?
|
Microbial Sensitivity Tests | 9 | 2019 | 143 | 0.680 |
Why?
|
Bevacizumab | 7 | 2019 | 281 | 0.680 |
Why?
|
Choroiditis | 2 | 2010 | 7 | 0.660 |
Why?
|
Middle Aged | 43 | 2024 | 25017 | 0.650 |
Why?
|
Drug Implants | 7 | 2023 | 34 | 0.640 |
Why?
|
Clinical Trials as Topic | 5 | 2020 | 1169 | 0.610 |
Why?
|
Retinal Vein Occlusion | 2 | 2014 | 8 | 0.600 |
Why?
|
Lasers, Semiconductor | 1 | 2016 | 2 | 0.590 |
Why?
|
Laser Therapy | 2 | 2020 | 142 | 0.580 |
Why?
|
Dexamethasone | 4 | 2019 | 326 | 0.580 |
Why?
|
Peptides | 1 | 2020 | 639 | 0.580 |
Why?
|
Light Coagulation | 2 | 2021 | 6 | 0.570 |
Why?
|
Male | 48 | 2024 | 40956 | 0.570 |
Why?
|
Drug Delivery Systems | 4 | 2022 | 178 | 0.550 |
Why?
|
Biological Availability | 9 | 2015 | 92 | 0.540 |
Why?
|
Facility Design and Construction | 1 | 2015 | 4 | 0.530 |
Why?
|
Administration, Oral | 8 | 2015 | 684 | 0.530 |
Why?
|
Vitreoretinopathy, Proliferative | 1 | 2015 | 4 | 0.520 |
Why?
|
Iris | 1 | 2015 | 5 | 0.520 |
Why?
|
Adrenal Cortex Hormones | 2 | 2013 | 263 | 0.520 |
Why?
|
Vision Disorders | 3 | 2016 | 75 | 0.520 |
Why?
|
Basement Membrane | 2 | 2019 | 54 | 0.520 |
Why?
|
Professional Practice | 1 | 2015 | 46 | 0.510 |
Why?
|
Efficiency, Organizational | 1 | 2015 | 58 | 0.510 |
Why?
|
Ophthalmologic Surgical Procedures | 1 | 2015 | 25 | 0.510 |
Why?
|
Fovea Centralis | 6 | 2021 | 21 | 0.510 |
Why?
|
Fibrinolysin | 2 | 2019 | 26 | 0.500 |
Why?
|
Aged, 80 and over | 20 | 2024 | 6501 | 0.500 |
Why?
|
Physical Examination | 1 | 2015 | 149 | 0.490 |
Why?
|
Stress, Mechanical | 1 | 2015 | 248 | 0.490 |
Why?
|
Retrospective Studies | 18 | 2022 | 8475 | 0.490 |
Why?
|
Surgical Wound Dehiscence | 2 | 2011 | 37 | 0.490 |
Why?
|
Uveitis, Posterior | 1 | 2013 | 1 | 0.480 |
Why?
|
Ambulatory Care Facilities | 1 | 2015 | 102 | 0.480 |
Why?
|
Female | 43 | 2024 | 44507 | 0.470 |
Why?
|
Cornea | 3 | 2019 | 69 | 0.450 |
Why?
|
Tissue Adhesions | 1 | 2013 | 50 | 0.450 |
Why?
|
Propylene Glycols | 1 | 2013 | 30 | 0.450 |
Why?
|
Eye Foreign Bodies | 1 | 2012 | 1 | 0.440 |
Why?
|
Suture Techniques | 2 | 2011 | 135 | 0.440 |
Why?
|
Eye Injuries, Penetrating | 1 | 2012 | 5 | 0.440 |
Why?
|
Glass | 1 | 2012 | 15 | 0.440 |
Why?
|
Sphingosine | 1 | 2013 | 71 | 0.430 |
Why?
|
Neovascularization, Pathologic | 1 | 2015 | 353 | 0.430 |
Why?
|
Career Choice | 1 | 2014 | 139 | 0.430 |
Why?
|
Chromatography, High Pressure Liquid | 9 | 2008 | 315 | 0.430 |
Why?
|
Peptide Fragments | 2 | 2019 | 460 | 0.420 |
Why?
|
Faculty, Medical | 1 | 2014 | 178 | 0.410 |
Why?
|
Endoscopy | 1 | 2015 | 332 | 0.410 |
Why?
|
Protein Kinase Inhibitors | 1 | 2016 | 589 | 0.410 |
Why?
|
Anti-Infective Agents | 2 | 2003 | 89 | 0.410 |
Why?
|
Wound Healing | 2 | 2011 | 344 | 0.400 |
Why?
|
Keratitis | 2 | 2019 | 22 | 0.400 |
Why?
|
Hydrogel, Polyethylene Glycol Dimethacrylate | 1 | 2011 | 31 | 0.390 |
Why?
|
Tissue Adhesives | 1 | 2011 | 23 | 0.390 |
Why?
|
Ischemia | 1 | 2013 | 243 | 0.390 |
Why?
|
Voriconazole | 8 | 2010 | 17 | 0.390 |
Why?
|
Fibrinolytic Agents | 1 | 2013 | 202 | 0.390 |
Why?
|
Prospective Studies | 16 | 2024 | 4210 | 0.390 |
Why?
|
Coccidioides | 1 | 2010 | 5 | 0.380 |
Why?
|
Fluconazole | 1 | 2010 | 10 | 0.380 |
Why?
|
Coccidioidomycosis | 1 | 2010 | 7 | 0.380 |
Why?
|
Bandages, Hydrocolloid | 1 | 2010 | 2 | 0.380 |
Why?
|
Multiple Sclerosis | 1 | 2013 | 262 | 0.380 |
Why?
|
Diagnostic Imaging | 1 | 2014 | 469 | 0.370 |
Why?
|
Diabetes Mellitus, Type 2 | 3 | 2022 | 1373 | 0.370 |
Why?
|
Specialization | 3 | 2021 | 65 | 0.350 |
Why?
|
Treatment Outcome | 12 | 2022 | 7988 | 0.350 |
Why?
|
Biocompatible Materials | 1 | 2011 | 193 | 0.350 |
Why?
|
Retinal Artery Occlusion | 1 | 2009 | 12 | 0.350 |
Why?
|
Cysts | 1 | 2010 | 104 | 0.350 |
Why?
|
Foramen Ovale, Patent | 1 | 2009 | 18 | 0.350 |
Why?
|
Glaucoma, Open-Angle | 4 | 2022 | 17 | 0.340 |
Why?
|
Aptamers, Nucleotide | 2 | 2006 | 23 | 0.340 |
Why?
|
Porphyrins | 2 | 2005 | 39 | 0.330 |
Why?
|
Inpatients | 3 | 2016 | 297 | 0.330 |
Why?
|
Photosensitizing Agents | 2 | 2005 | 48 | 0.320 |
Why?
|
Phenylacetates | 1 | 2007 | 3 | 0.320 |
Why?
|
Benzeneacetamides | 1 | 2007 | 11 | 0.320 |
Why?
|
Drug Carriers | 2 | 2005 | 81 | 0.320 |
Why?
|
Polyethylene Glycols | 1 | 2010 | 363 | 0.310 |
Why?
|
Immunosuppressive Agents | 1 | 2013 | 977 | 0.300 |
Why?
|
Collagen | 2 | 2005 | 269 | 0.300 |
Why?
|
Appointments and Schedules | 2 | 2019 | 53 | 0.300 |
Why?
|
Genetic Therapy | 3 | 2018 | 342 | 0.290 |
Why?
|
Cataract | 3 | 2021 | 86 | 0.290 |
Why?
|
Indocyanine Green | 3 | 2015 | 22 | 0.270 |
Why?
|
Prototheca | 1 | 2005 | 1 | 0.270 |
Why?
|
Eye Infections | 1 | 2005 | 2 | 0.270 |
Why?
|
Vision, Low | 2 | 2015 | 15 | 0.270 |
Why?
|
Gastrointestinal Microbiome | 2 | 2022 | 455 | 0.270 |
Why?
|
Genetic Testing | 2 | 2021 | 535 | 0.260 |
Why?
|
Retinal Photoreceptor Cell Inner Segment | 2 | 2017 | 4 | 0.260 |
Why?
|
Follow-Up Studies | 8 | 2017 | 3636 | 0.260 |
Why?
|
Clinical Protocols | 2 | 2016 | 156 | 0.260 |
Why?
|
Artificial Intelligence | 3 | 2023 | 298 | 0.260 |
Why?
|
Coloring Agents | 2 | 2015 | 64 | 0.260 |
Why?
|
Antineoplastic Agents | 1 | 2016 | 2357 | 0.250 |
Why?
|
Injections | 8 | 2009 | 109 | 0.250 |
Why?
|
Quality of Life | 3 | 2022 | 1583 | 0.250 |
Why?
|
Drug Therapy, Combination | 3 | 2019 | 894 | 0.250 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2018 | 864 | 0.240 |
Why?
|
Diet, High-Fat | 2 | 2022 | 114 | 0.240 |
Why?
|
Scleral Buckling | 2 | 2021 | 18 | 0.240 |
Why?
|
Tonometry, Ocular | 3 | 2016 | 10 | 0.240 |
Why?
|
Phacoemulsification | 2 | 2021 | 16 | 0.230 |
Why?
|
Adult | 20 | 2021 | 25640 | 0.230 |
Why?
|
Syphilis, Congenital | 1 | 2002 | 2 | 0.220 |
Why?
|
Retinal Telangiectasis | 1 | 2022 | 5 | 0.220 |
Why?
|
Steroids | 3 | 2019 | 177 | 0.220 |
Why?
|
Chronic Disease | 2 | 2022 | 970 | 0.210 |
Why?
|
Inflammation | 3 | 2023 | 920 | 0.200 |
Why?
|
Retinal Necrosis Syndrome, Acute | 1 | 2021 | 5 | 0.200 |
Why?
|
Biosimilar Pharmaceuticals | 1 | 2021 | 20 | 0.200 |
Why?
|
Retinal Neovascularization | 1 | 2020 | 5 | 0.200 |
Why?
|
Insulin | 2 | 2024 | 1160 | 0.200 |
Why?
|
Sulfonamides | 1 | 2023 | 300 | 0.190 |
Why?
|
Half-Life | 1 | 2020 | 96 | 0.190 |
Why?
|
Total Quality Management | 1 | 2020 | 34 | 0.190 |
Why?
|
Administration, Topical | 4 | 2018 | 95 | 0.190 |
Why?
|
Hemangioblastoma | 1 | 2020 | 12 | 0.180 |
Why?
|
Integrins | 1 | 2020 | 76 | 0.180 |
Why?
|
von Hippel-Lindau Disease | 1 | 2020 | 17 | 0.180 |
Why?
|
Choroid Hemorrhage | 1 | 2019 | 3 | 0.180 |
Why?
|
Angiography | 2 | 2020 | 208 | 0.180 |
Why?
|
Medicare | 4 | 2024 | 406 | 0.180 |
Why?
|
Universities | 1 | 2021 | 135 | 0.180 |
Why?
|
Micrococcaceae | 1 | 2019 | 3 | 0.180 |
Why?
|
Ergonomics | 1 | 2019 | 21 | 0.180 |
Why?
|
United States | 7 | 2024 | 6665 | 0.180 |
Why?
|
Ocular Hypertension | 1 | 2019 | 7 | 0.170 |
Why?
|
Gram-Positive Bacterial Infections | 1 | 2019 | 47 | 0.170 |
Why?
|
Case-Control Studies | 4 | 2024 | 1804 | 0.170 |
Why?
|
Machine Learning | 1 | 2021 | 232 | 0.170 |
Why?
|
Double-Blind Method | 5 | 2016 | 1823 | 0.170 |
Why?
|
Burnout, Professional | 1 | 2020 | 94 | 0.170 |
Why?
|
Retinal Dystrophies | 1 | 2018 | 1 | 0.170 |
Why?
|
Delivery of Health Care | 2 | 2020 | 426 | 0.170 |
Why?
|
Time Factors | 5 | 2019 | 5209 | 0.170 |
Why?
|
Pharmaceutical Preparations | 1 | 2019 | 92 | 0.160 |
Why?
|
Fungemia | 2 | 2010 | 15 | 0.160 |
Why?
|
Vitreous Detachment | 1 | 2017 | 3 | 0.150 |
Why?
|
Multicenter Studies as Topic | 1 | 2018 | 159 | 0.150 |
Why?
|
Functional Laterality | 2 | 2010 | 201 | 0.150 |
Why?
|
Ophthalmic Solutions | 3 | 2005 | 16 | 0.150 |
Why?
|
Staphylococcal Infections | 1 | 2019 | 255 | 0.150 |
Why?
|
Depression | 1 | 2021 | 473 | 0.150 |
Why?
|
Drug Approval | 2 | 2018 | 62 | 0.150 |
Why?
|
Platelet-Derived Growth Factor | 1 | 2017 | 67 | 0.150 |
Why?
|
United States Food and Drug Administration | 2 | 2018 | 127 | 0.150 |
Why?
|
Staphylococcus aureus | 1 | 2019 | 263 | 0.150 |
Why?
|
Drugs, Investigational | 1 | 2017 | 37 | 0.150 |
Why?
|
Bacteria | 2 | 2015 | 447 | 0.140 |
Why?
|
Protein Binding | 1 | 2020 | 1456 | 0.140 |
Why?
|
Subretinal Fluid | 1 | 2016 | 2 | 0.140 |
Why?
|
Accidental Falls | 1 | 2016 | 50 | 0.140 |
Why?
|
Drug Administration Routes | 1 | 2015 | 19 | 0.140 |
Why?
|
Retinal Degeneration | 1 | 2016 | 28 | 0.140 |
Why?
|
Optic Nerve | 3 | 2001 | 35 | 0.140 |
Why?
|
Animals | 9 | 2022 | 26581 | 0.140 |
Why?
|
Cohort Studies | 3 | 2020 | 2767 | 0.140 |
Why?
|
Platelet Aggregation Inhibitors | 2 | 2022 | 134 | 0.140 |
Why?
|
Eye Pain | 1 | 2015 | 4 | 0.130 |
Why?
|
Anterior Eye Segment | 1 | 2015 | 6 | 0.130 |
Why?
|
Ophthalmoscopy | 1 | 2015 | 12 | 0.130 |
Why?
|
Therapeutic Equivalency | 1 | 2015 | 12 | 0.130 |
Why?
|
Eyeglasses | 1 | 2015 | 8 | 0.130 |
Why?
|
Planning Techniques | 1 | 2015 | 10 | 0.130 |
Why?
|
Health Literacy | 1 | 2016 | 70 | 0.130 |
Why?
|
Triamcinolone Acetonide | 2 | 2022 | 8 | 0.130 |
Why?
|
Antibiotic Prophylaxis | 1 | 2015 | 71 | 0.130 |
Why?
|
Young Adult | 5 | 2021 | 5974 | 0.130 |
Why?
|
Epiretinal Membrane | 1 | 2014 | 2 | 0.120 |
Why?
|
Surveys and Questionnaires | 2 | 2015 | 2501 | 0.120 |
Why?
|
Vitreous Hemorrhage | 2 | 2011 | 11 | 0.120 |
Why?
|
Anticoagulants | 2 | 2022 | 408 | 0.120 |
Why?
|
Low-Level Light Therapy | 1 | 2013 | 15 | 0.120 |
Why?
|
Drug Substitution | 1 | 2013 | 25 | 0.110 |
Why?
|
Fingolimod Hydrochloride | 1 | 2013 | 29 | 0.110 |
Why?
|
Multimodal Imaging | 1 | 2014 | 110 | 0.110 |
Why?
|
Patient Readmission | 1 | 2016 | 329 | 0.110 |
Why?
|
Accidents, Occupational | 1 | 2012 | 8 | 0.110 |
Why?
|
Receptors, Glucocorticoid | 1 | 2014 | 120 | 0.110 |
Why?
|
Fourier Analysis | 2 | 2010 | 125 | 0.110 |
Why?
|
Retinal Photoreceptor Cell Outer Segment | 1 | 2012 | 3 | 0.110 |
Why?
|
Postoperative Complications | 2 | 2016 | 2207 | 0.110 |
Why?
|
Chorioretinitis | 1 | 2012 | 10 | 0.110 |
Why?
|
Fundus Oculi | 3 | 2018 | 33 | 0.110 |
Why?
|
West Nile Fever | 1 | 2012 | 21 | 0.110 |
Why?
|
Risk Factors | 5 | 2024 | 5416 | 0.100 |
Why?
|
Hot Temperature | 1 | 2012 | 206 | 0.100 |
Why?
|
Biomedical Research | 1 | 2016 | 375 | 0.100 |
Why?
|
Cross-Sectional Studies | 4 | 2021 | 1621 | 0.100 |
Why?
|
Electronic Health Records | 1 | 2015 | 319 | 0.100 |
Why?
|
Glaucoma | 2 | 2012 | 30 | 0.100 |
Why?
|
Academic Medical Centers | 1 | 2014 | 379 | 0.100 |
Why?
|
Retinal Hemorrhage | 1 | 2010 | 9 | 0.100 |
Why?
|
Needles | 1 | 2010 | 35 | 0.100 |
Why?
|
Equipment Contamination | 1 | 2010 | 22 | 0.100 |
Why?
|
Practice Guidelines as Topic | 1 | 2018 | 1034 | 0.100 |
Why?
|
Ink | 1 | 2010 | 4 | 0.100 |
Why?
|
Ophthalmologists | 2 | 2020 | 5 | 0.090 |
Why?
|
Mass Screening | 1 | 2015 | 617 | 0.090 |
Why?
|
Carbon | 1 | 2010 | 80 | 0.090 |
Why?
|
Eye Proteins | 1 | 2011 | 128 | 0.090 |
Why?
|
Reproducibility of Results | 2 | 2020 | 2705 | 0.090 |
Why?
|
Preoperative Care | 3 | 2014 | 394 | 0.090 |
Why?
|
Polymers | 1 | 2011 | 202 | 0.090 |
Why?
|
Combined Modality Therapy | 1 | 2013 | 1685 | 0.090 |
Why?
|
Retinal Pigment Epithelium | 2 | 2022 | 12 | 0.090 |
Why?
|
Observer Variation | 1 | 2010 | 602 | 0.080 |
Why?
|
Anterior Chamber | 1 | 2008 | 9 | 0.080 |
Why?
|
Lenses, Intraocular | 1 | 2007 | 12 | 0.080 |
Why?
|
Catheterization | 1 | 2009 | 232 | 0.080 |
Why?
|
Chromosome Mapping | 1 | 2011 | 1074 | 0.080 |
Why?
|
Electroretinography | 2 | 2004 | 76 | 0.080 |
Why?
|
Transcriptome | 2 | 2022 | 580 | 0.080 |
Why?
|
History, 21st Century | 2 | 2018 | 175 | 0.070 |
Why?
|
Osmolar Concentration | 2 | 2004 | 181 | 0.070 |
Why?
|
Health Status Indicators | 1 | 2007 | 105 | 0.070 |
Why?
|
Pigment Epithelium of Eye | 1 | 2006 | 13 | 0.070 |
Why?
|
History, 20th Century | 2 | 2018 | 312 | 0.070 |
Why?
|
Mupirocin | 1 | 2006 | 6 | 0.070 |
Why?
|
Conjunctiva | 1 | 2006 | 19 | 0.070 |
Why?
|
Gram-Positive Bacteria | 1 | 2006 | 18 | 0.070 |
Why?
|
Biodegradation, Environmental | 1 | 2005 | 17 | 0.070 |
Why?
|
Corneal Dystrophies, Hereditary | 1 | 2005 | 5 | 0.070 |
Why?
|
Amphotericin B | 1 | 2005 | 34 | 0.070 |
Why?
|
Psychometrics | 1 | 2007 | 327 | 0.070 |
Why?
|
Genes, Recessive | 1 | 2005 | 87 | 0.070 |
Why?
|
Blood | 1 | 2005 | 69 | 0.070 |
Why?
|
Antibodies, Monoclonal | 2 | 2010 | 1376 | 0.070 |
Why?
|
Adolescent | 4 | 2018 | 8979 | 0.070 |
Why?
|
Nasal Mucosa | 1 | 2006 | 186 | 0.070 |
Why?
|
Proteoglycans | 1 | 2005 | 121 | 0.060 |
Why?
|
Histoplasmosis | 1 | 2005 | 25 | 0.060 |
Why?
|
Peptides, Cyclic | 1 | 2005 | 43 | 0.060 |
Why?
|
Candidiasis | 1 | 2005 | 36 | 0.060 |
Why?
|
Fatal Outcome | 1 | 2005 | 293 | 0.060 |
Why?
|
Regional Blood Flow | 2 | 2021 | 197 | 0.060 |
Why?
|
Dose-Response Relationship, Drug | 3 | 2019 | 1961 | 0.060 |
Why?
|
Tablets | 1 | 2006 | 118 | 0.060 |
Why?
|
Methyldopa | 1 | 2024 | 3 | 0.060 |
Why?
|
Sulfonylurea Compounds | 1 | 2024 | 64 | 0.060 |
Why?
|
Models, Biological | 1 | 2011 | 1749 | 0.060 |
Why?
|
International Classification of Diseases | 1 | 2024 | 69 | 0.060 |
Why?
|
Fungi | 1 | 2004 | 65 | 0.060 |
Why?
|
Atrophy | 1 | 2023 | 117 | 0.060 |
Why?
|
Complement Inactivating Agents | 1 | 2023 | 4 | 0.060 |
Why?
|
Endothelial Growth Factors | 1 | 2023 | 55 | 0.060 |
Why?
|
Biological Transport | 1 | 2004 | 396 | 0.060 |
Why?
|
Microbiological Techniques | 1 | 2022 | 24 | 0.060 |
Why?
|
Laser-Doppler Flowmetry | 5 | 2001 | 20 | 0.050 |
Why?
|
Pilot Projects | 1 | 2005 | 839 | 0.050 |
Why?
|
Drug Administration Schedule | 1 | 2004 | 916 | 0.050 |
Why?
|
Incidence | 2 | 2020 | 1576 | 0.050 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2007 | 567 | 0.050 |
Why?
|
Lens Implantation, Intraocular | 1 | 2021 | 23 | 0.050 |
Why?
|
Blood Flow Velocity | 5 | 2001 | 197 | 0.050 |
Why?
|
Postoperative Hemorrhage | 1 | 2022 | 46 | 0.050 |
Why?
|
Capillaries | 1 | 2021 | 91 | 0.050 |
Why?
|
Child | 2 | 2010 | 6926 | 0.050 |
Why?
|
Healthy Volunteers | 1 | 2021 | 143 | 0.050 |
Why?
|
Neoplasms | 1 | 2016 | 2897 | 0.050 |
Why?
|
Lasers | 1 | 2021 | 106 | 0.050 |
Why?
|
Hypoglycemic Agents | 1 | 2024 | 378 | 0.050 |
Why?
|
False Positive Reactions | 1 | 2020 | 216 | 0.050 |
Why?
|
Algorithms | 2 | 2023 | 1830 | 0.050 |
Why?
|
Patient Comfort | 1 | 2019 | 7 | 0.050 |
Why?
|
Proof of Concept Study | 1 | 2019 | 38 | 0.050 |
Why?
|
Cost-Benefit Analysis | 1 | 2022 | 451 | 0.050 |
Why?
|
Sequence Analysis, RNA | 1 | 2021 | 217 | 0.050 |
Why?
|
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2019 | 74 | 0.040 |
Why?
|
Risk Management | 1 | 2019 | 43 | 0.040 |
Why?
|
Endotamponade | 1 | 2019 | 4 | 0.040 |
Why?
|
Posture | 1 | 2019 | 125 | 0.040 |
Why?
|
Disease Progression | 1 | 2023 | 1531 | 0.040 |
Why?
|
Global Health | 1 | 2020 | 193 | 0.040 |
Why?
|
cis-trans-Isomerases | 1 | 2018 | 1 | 0.040 |
Why?
|
Dependovirus | 1 | 2018 | 33 | 0.040 |
Why?
|
Delayed-Action Preparations | 1 | 2018 | 116 | 0.040 |
Why?
|
Swine | 1 | 2019 | 555 | 0.040 |
Why?
|
Operating Rooms | 1 | 2019 | 126 | 0.040 |
Why?
|
Time-to-Treatment | 1 | 2019 | 97 | 0.040 |
Why?
|
Mice | 2 | 2022 | 11352 | 0.040 |
Why?
|
Feasibility Studies | 1 | 2019 | 751 | 0.040 |
Why?
|
Equipment Design | 1 | 2018 | 406 | 0.040 |
Why?
|
Genetic Vectors | 1 | 2018 | 439 | 0.040 |
Why?
|
Hypertension | 2 | 2010 | 1141 | 0.040 |
Why?
|
Prevalence | 1 | 2021 | 1239 | 0.040 |
Why?
|
Surgical Flaps | 1 | 2019 | 241 | 0.040 |
Why?
|
Pedigree | 2 | 2011 | 966 | 0.040 |
Why?
|
Leber Congenital Amaurosis | 1 | 2016 | 1 | 0.040 |
Why?
|
Predictive Value of Tests | 1 | 2020 | 1673 | 0.030 |
Why?
|
Problem Solving | 1 | 2015 | 54 | 0.030 |
Why?
|
Drug Combinations | 1 | 2016 | 224 | 0.030 |
Why?
|
Vision Tests | 1 | 2015 | 20 | 0.030 |
Why?
|
Photoreceptor Cells, Vertebrate | 1 | 2015 | 9 | 0.030 |
Why?
|
Blindness | 1 | 2015 | 41 | 0.030 |
Why?
|
Mutation | 1 | 2005 | 3967 | 0.030 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2016 | 243 | 0.030 |
Why?
|
Patient Discharge | 1 | 2016 | 300 | 0.030 |
Why?
|
Stem Cell Transplantation | 1 | 2015 | 183 | 0.030 |
Why?
|
Aging | 1 | 1998 | 691 | 0.030 |
Why?
|
Disease Models, Animal | 1 | 2019 | 2232 | 0.030 |
Why?
|
Postoperative Care | 1 | 2014 | 221 | 0.030 |
Why?
|
Trabeculectomy | 1 | 2012 | 3 | 0.030 |
Why?
|
Cell Survival | 1 | 2015 | 969 | 0.030 |
Why?
|
Anti-Inflammatory Agents | 1 | 2015 | 339 | 0.030 |
Why?
|
Oxidative Stress | 1 | 2015 | 447 | 0.030 |
Why?
|
Exotropia | 1 | 2011 | 2 | 0.030 |
Why?
|
Amblyopia | 1 | 2011 | 7 | 0.030 |
Why?
|
Coloboma | 1 | 2011 | 12 | 0.020 |
Why?
|
Propionibacterium acnes | 1 | 2010 | 6 | 0.020 |
Why?
|
Epidemiologic Studies | 1 | 2010 | 17 | 0.020 |
Why?
|
Staphylococcus epidermidis | 1 | 2010 | 14 | 0.020 |
Why?
|
Povidone-Iodine | 1 | 2010 | 8 | 0.020 |
Why?
|
Rats, Sprague-Dawley | 2 | 2004 | 1219 | 0.020 |
Why?
|
Microsatellite Repeats | 1 | 2011 | 144 | 0.020 |
Why?
|
Chromosomes, Human, Pair 6 | 1 | 2011 | 125 | 0.020 |
Why?
|
Sex Distribution | 1 | 2010 | 173 | 0.020 |
Why?
|
Prognosis | 1 | 2017 | 3674 | 0.020 |
Why?
|
Blood Pressure | 3 | 2001 | 1143 | 0.020 |
Why?
|
Hospitalization | 1 | 2015 | 848 | 0.020 |
Why?
|
Genetic Linkage | 1 | 2011 | 623 | 0.020 |
Why?
|
Illinois | 1 | 2010 | 462 | 0.020 |
Why?
|
Optic Disk | 2 | 1999 | 13 | 0.020 |
Why?
|
Maximum Tolerated Dose | 1 | 2009 | 270 | 0.020 |
Why?
|
Haplotypes | 1 | 2011 | 642 | 0.020 |
Why?
|
Blood Circulation | 2 | 1998 | 29 | 0.020 |
Why?
|
Disability Evaluation | 1 | 2009 | 136 | 0.020 |
Why?
|
Candida | 1 | 2008 | 17 | 0.020 |
Why?
|
Linear Models | 1 | 2009 | 421 | 0.020 |
Why?
|
Antihypertensive Agents | 1 | 2012 | 521 | 0.020 |
Why?
|
Rats | 2 | 2004 | 3990 | 0.020 |
Why?
|
Ointments | 1 | 2006 | 12 | 0.020 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2012 | 1204 | 0.020 |
Why?
|
Corneal Topography | 1 | 2005 | 8 | 0.020 |
Why?
|
Bacteriological Techniques | 1 | 2006 | 39 | 0.020 |
Why?
|
Consanguinity | 1 | 2005 | 73 | 0.020 |
Why?
|
Eye Abnormalities | 1 | 2005 | 41 | 0.020 |
Why?
|
Echinocandins | 1 | 2005 | 5 | 0.020 |
Why?
|
Severity of Illness Index | 1 | 2011 | 1801 | 0.020 |
Why?
|
Lipopeptides | 1 | 2005 | 16 | 0.020 |
Why?
|
Infusions, Intravenous | 1 | 2005 | 429 | 0.020 |
Why?
|
Syndrome | 1 | 2005 | 446 | 0.010 |
Why?
|
DNA Mutational Analysis | 1 | 2005 | 526 | 0.010 |
Why?
|
Exons | 1 | 2005 | 450 | 0.010 |
Why?
|
Necrosis | 1 | 2003 | 204 | 0.010 |
Why?
|
Amino Acid Sequence | 1 | 2005 | 2062 | 0.010 |
Why?
|
Visual Fields | 1 | 2001 | 98 | 0.010 |
Why?
|
Molecular Sequence Data | 1 | 2005 | 3030 | 0.010 |
Why?
|
Sphygmomanometers | 1 | 1999 | 4 | 0.010 |
Why?
|
Optic Nerve Diseases | 1 | 1998 | 18 | 0.010 |
Why?
|
Blood Volume | 1 | 1998 | 51 | 0.010 |
Why?
|